Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Forecast Score | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT | SAREPTA THERAPEUTICS INC | $11.23B | $117.79 | $192.53 | 63.45% | Strong Buy | 15 | 40.37% | 177.73% | 150.61% | 47.37% | ||||
| KRYS | KRYSTAL BIOTECH INC | $5.03B | $175.00 | $211.80 | 21.03% | Buy | 5 | 56.29% | 27.13% | 29.49% | 26.96% | ||||
| TGTX | TG THERAPEUTICS INC | $3.30B | $21.31 | $33.60 | 57.67% | Strong Buy | 5 | 24.29% | 28.42% | 228.00% | 100.91% | ||||
| CORT | CORCEPT THERAPEUTICS INC | $4.67B | $44.66 | $66.50 | 48.90% | Strong Buy | 4 | 13.86% | 23.20% | 49.60% | 41.38% | ||||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.34B | $19.73 | $30.00 | 52.05% | Strong Buy | 4 | 13.78% | 57.76% | 45.44% | 39.15% | ||||
| HALO | HALOZYME THERAPEUTICS INC | $6.82B | $53.85 | $60.44 | 12.25% | Buy | 9 | 16.55% | 31.16% | 347.75% | 51.10% | ||||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.95B | $34.38 | $51.25 | 49.07% | Strong Buy | 4 | 11.82% | 30.74% | 51.81% | 32.51% | ||||
| ADMA | ADMA BIOLOGICS INC | $4.70B | $20.18 | $15.50 | -23.19% | Strong Buy | 4 | 17.77% | 69.00% | 107.71% | 53.87% | ||||
| VCEL | VERICEL CORP | $2.01B | $41.06 | $57.83 | 40.85% | Strong Buy | 6 | 22.21% | 331.60% | 28.86% | 18.61% | ||||
| INCY | INCYTE CORP | $12.67B | $65.76 | $71.90 | 9.34% | Buy | 10 | 9.67% | 171.16% | 52.41% | 33.69% | ||||
| ACAD | ACADIA PHARMACEUTICALS INC | $2.44B | $14.73 | $24.39 | 65.55% | Buy | 13 | 9.42% | 96.04% | 64.74% | 36.60% | ||||
| NVO | NOVO NORDISK A S | $531.14B | $117.77 | $160.00 | 35.86% | Strong Buy | 3 | 16.08% | 19.32% | 144.27% | 43.95% | ||||
| FENC | FENNEC PHARMACEUTICALS INC | $125.06M | $4.57 | $14.00 | 206.35% | Buy | 2 | 16.92% | 114.22% | -4,063.31% | 87.30% | ||||
| RPRX | ROYALTY PHARMA PLC | $16.36B | $27.57 | $42.00 | 52.34% | Strong Buy | 4 | 14.33% | 69.29% | 27.84% | 15.38% | ||||
| MNKD | MANNKIND CORP | $1.74B | $6.34 | $8.63 | 36.04% | Strong Buy | 4 | 14.77% | 71.63% | -45.07% | 22.92% | ||||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $13.13B | $68.96 | $98.29 | 42.54% | Strong Buy | 17 | 10.05% | 46.65% | 18.62% | 13.93% | ||||
| LGND | LIGAND PHARMACEUTICALS INC | $1.87B | $102.62 | $131.80 | 28.44% | Buy | 5 | 13.91% | 34.23% | N/A | N/A | ||||
| PBYI | PUMA BIOTECHNOLOGY INC | $130.46M | $2.66 | $7.00 | 163.16% | Buy | 1 | 2.05% | 45.05% | 75.83% | 17.94% | ||||
| EXEL | EXELIXIS INC | $7.50B | $26.31 | $28.33 | 7.69% | Buy | 9 | 4.51% | 18.33% | 36.69% | 28.05% | ||||
| ADXN | ADDEX THERAPEUTICS LTD | $7.34M | $9.34 | $30.00 | 221.37% | Buy | 1 | -29.10% | 942.55% | -184.94% | -170.82% | ||||
| TECH | BIO-TECHNE CORP | $11.66B | $73.52 | $82.80 | 12.62% | Buy | 5 | 7.66% | 29.45% | N/A | N/A | ||||
| MDXG | MIMEDX GROUP INC | $823.60M | $5.61 | $11.33 | 102.01% | Strong Buy | 3 | 13.93% | 12.56% | 64.65% | 47.20% | ||||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.70B | $108.52 | $166.17 | 53.12% | Buy | 12 | 5.73% | 46.35% | N/A | N/A | ||||
| GMAB | GENMAB A | $15.50B | $23.43 | $44.50 | 89.93% | Strong Buy | 4 | 16.83% | 17.11% | 4.36% | 3.50% | ||||
| UTHR | UNITED THERAPEUTICS CORP | $15.57B | $349.85 | $374.22 | 6.97% | Strong Buy | 9 | 6.73% | 5.80% | 23.68% | 20.06% | ||||
| REGN | REGENERON PHARMACEUTICALS INC | $109.80B | $996.05 | $1.15k | 14.97% | Strong Buy | 18 | 6.88% | 4.42% | 22.49% | 17.58% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.